Business
Korsana’s lead program uses a next-generation shuttling technology to improve delivery into the brain and lower the incidence of amyloid-related imaging abnormalities.
FEATURED STORIES
Suppliers are investing in production to support deals with AstraZeneca, Bayer and other drugmakers that are advancing radioisotope-based cancer therapies.
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Kidney disease hasn’t been an area of vibrant transformation, but it is emerging as a promising and area for diagnostic and therapeutic investigation following an explosion of foundational technologies in recent years, according to speakers at BIO-Europe® Digital, held virtually October 26-29.
Through this collaboration, Insitro will utilize its proprietary platform, Insitro Human (ISH), to create induced pluripotent stem cell (iPSC) derived disease models for both diseases.
Texas wants to get the word out: It’s not just for oil and pipelines anymore. The Lone Star State is a rapidly emerging biopharma hub, with more than just a lone focus on oncology.
Novartis is harnessing the power of Molecular Partners AG’s DARPin platform to develop two therapeutic candidates that could both be used to prevent and treat COVID-19 infection.
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
The agreement provides exclusive rights to EQRx for CStone’s late-stage immuno-oncology anti-PD-L1 monoclonal antibody sugemalimab and anti-PD-1 CS1003.
Excess mortality rates in the U.S. remain high, despite a steady decline since mid-December.
Chasity’s story stands in hopeful defiance of a typically grim acute lymphocytic leukemia prognosis. In this case, CAR T cell therapy has proven to be a uniquely viable option.
South Korea, on the other hand, indicated they would continue their state-run vaccination program because they did not find a direct link between the deaths and the vaccinations.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.